These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761 [TBL] [Abstract][Full Text] [Related]
10. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. Pietras K; Hanahan D J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593 [TBL] [Abstract][Full Text] [Related]
11. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751 [TBL] [Abstract][Full Text] [Related]
12. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib]. Nishida T; Omori T; Ueshima S Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of c-Kit is not required for reversal of hyperglycemia by imatinib in NOD mice. Lau J; Zhou Q; Sutton SE; Herman AE; Schmedt C; Glynne R PLoS One; 2014; 9(1):e84900. PubMed ID: 24454763 [TBL] [Abstract][Full Text] [Related]
14. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. De Pas T; Toffalorio F; Colombo P; Trifirò G; Pelosi G; Vigna PD; Manzotti M; Agostini M; de Braud F J Thorac Oncol; 2008 Aug; 3(8):938-41. PubMed ID: 18670317 [TBL] [Abstract][Full Text] [Related]
15. Hits and misses in targeting pediatric cancers. Bernstein ML Pediatr Blood Cancer; 2009 Jul; 52(7):751-2. PubMed ID: 19185009 [No Abstract] [Full Text] [Related]
16. [Consensus on the medical treatment of gastrointestinal stromal tumors]. Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652 [No Abstract] [Full Text] [Related]
17. Second line therapies for the treatment of gastrointestinal stromal tumor. Joensuu H Curr Opin Oncol; 2007 Jul; 19(4):353-8. PubMed ID: 17545799 [TBL] [Abstract][Full Text] [Related]
18. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
19. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812 [TBL] [Abstract][Full Text] [Related]